Company Profile
Ovid Therapeutics Stock Price, News & Catalysts
- Ticker:
- OVID
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.80 USD (+2.19%)
Close
Last updated: August 21, 2026
448M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, OVID closed up 2.19% at $2.80. No new same-company headline was identified in the current news window.
Company overview
Neurological Small-Molecule Company
Ovid Therapeutics develops medicines for epilepsies and other intractable brain disorders.
OV329
OV329 is a next-generation GABA aminotransferase inhibitor being developed for focal-onset seizures, tuberous sclerosis complex seizures, and infantile spasms.
OV4071
OV4071 is an oral direct activator of the potassium-chloride cotransporter KCC2 and is intended to restore inhibitory neuronal signaling.
Future catalysts
- Initiation of the OV4071 ketamine-challenge study in the second half of 2026.
- Initiation of a Phase 2 proof-of-concept study of OV4071 in acute schizophrenia in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ovid Therapeutics (OVID)?
Ovid Therapeutics (OVID) most recently closed at 2.80 USD, a +2.19% move versus the previous session.
What is the market cap of Ovid Therapeutics (OVID)?
Ovid Therapeutics currently has a market capitalization of 448M USD on BioPharmSignal.
What does Ovid Therapeutics do?
Neurological Small-Molecule Company Ovid Therapeutics develops medicines for epilepsies and other intractable brain disorders. OV329 OV329 is a next-generation GABA aminotransferase inhibitor being developed for focal-onset seizures, tuberous sclerosis complex seizures, and infantile spasms. OV4071 OV4071 is an oral direct activator of the...
On which exchange is OVID stock listed?
Ovid Therapeutics (OVID) is associated with NASDAQ, United States, Biopharma.
What is proof-of-concept?
Initiation of a Phase 2 proof-of-concept study of OV4071 in acute schizophrenia in 2027.
Which conditions is Ovid Therapeutics targeting with proof-of-concept?
Initiation of a Phase 2 proof-of-concept study of OV4071 in acute schizophrenia in 2027.
How does Ovid Therapeutics describe recent progress with proof-of-concept?
Initiation of a Phase 2 proof-of-concept study of OV4071 in acute schizophrenia in 2027.
What is Neurological?
Neurological Small-Molecule Company Ovid Therapeutics develops medicines for epilepsies and other intractable brain disorders.